DANIELA ANDRADE FERRARO
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/43 - Laboratório de Medicina Nuclear, Hospital das Clínicas, Faculdade de Medicina
LIM/43 - Laboratório de Medicina Nuclear, Hospital das Clínicas, Faculdade de Medicina
5 resultados
Resultados de Busca
Agora exibindo 1 - 5 de 5
- Diagnostic performance of Ga-68-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study(2021) FERRARO, Daniela A.; BECKER, Anton S.; KRANZBUHLER, Benedikt; MEBERT, Iliana; BALTENSPERGER, Anka; ZEIMPEKIS, Konstantinos G.; GRUNIG, Hannes; MESSERLI, Michael; RUPP, Niels J.; RUESCHOFF, Jan H.; MORTEZAVI, Ashkan; DONATI, Olivio F.; SAPIENZA, Marcelo T.; EBERLI, Daniel; BURGER, Irene A.Purpose Ultrasound-guided biopsy (US biopsy) with 10-12 cores has a suboptimal sensitivity for clinically significant prostate cancer (sigPCa). If US biopsy is negative, magnetic resonance imaging (MRI)-guided biopsy is recommended, despite a low specificity for lesions with score 3-5 on Prostate Imaging Reporting and Data System (PIRADS). Screening and biopsy guidance using an imaging modality with high accuracy could reduce the number of unnecessary biopsies, reducing side effects. The aim of this study was to assess the performance of positron emission tomography/MRI with Ga-68-labeled prostate-specific membrane antigen (PSMA-PET/MRI) to detect and localize primary sigPCa (ISUP grade group 3 and/or cancer core length >= 6 mm) and guide biopsy. Methods Prospective, open-label, single-center, non-randomized, diagnostic accuracy study including patients with suspected PCa by elevation of prostate-specific antigen (PSA) level and a suspicious lesion (PIRADS >= 3) on multiparametric MRI (mpMRI). Forty-two patients underwent PSMA-PET/MRI followed by both PSMA-PET/MRI-guided and section-based saturation template biopsy between May 2017 and February 2019. Primary outcome was the accuracy of PSMA-PET/MRI for biopsy guidance using section-based saturation template biopsy as the reference standard. Results SigPCa was found in 62% of the patients. Patient-based sensitivity, specificity, negative and positive predictive value, and accuracy for sigPCa were 96%, 81%, 93%, 89%, and 90%, respectively. One patient had PSMA-negative sigPCa. Eight of nine false-positive lesions corresponded to cancer on prostatectomy and one in six false-negative lesions was negative on prostatectomy. Conclusion PSMA-PET/MRI has a high accuracy for detecting sigPCa and is a promising tool to select patients with suspicion of PCa for biopsy.
conferenceObject Quantitative imaging parameters to predict local staging of prostate cancer in intermediate- to high-risk patients(2021) LAUDICELLA, R.; SKAWRAN, S.; FERRARO, D. A.; MUHLEMATTER, U.; MAURER, A.; GRUNIG, H.; DONATI, O.; EBERLI, D.; BURGER, I. A.- What's behind Ga-68-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns(2021) RUSCHOFF, Jan H.; FERRARO, Daniela A.; MUEHLEMATTER, Urs J.; LAUDICELLA, Riccardo; HERMANNS, Thomas; RODEWALD, Ann-Katrin; MOCH, Holger; EBERLI, Daniel; BURGER, Irene A.; RUPP, Niels J.Purpose Prostate-specific membrane antigen (PSMA-) PET has become a promising tool in staging and restaging of prostate carcinoma (PCa). However, specific primary tumour features might impact accuracy of PSMA-PET for PCa detection. We investigated histopathological parameters and immunohistochemical PSMA expression patterns on radical prostatectomy (RPE) specimens and correlated them to the corresponding Ga-68-PSMA-11-PET examinations. Methods RPE specimens of 62 patients with preoperative Ga-68-PSMA-11-PET between 2016 and 2018 were analysed. WHO/ISUP grade groups, growth pattern (expansive vs. infiltrative), tumour area and diameter as well as immunohistochemical PSMA heterogeneity, intensity and negative tumour area (PSMA(%neg)) were correlated with spatially corresponding SUVmax on Ga-68-PSMA-11-PET in a multidisciplinary analysis. Results All tumours showed medium to strong membranous (2-3 +) and weak to strong cytoplasmic (1-3 +) PSMA expression. Heterogeneously expressed PSMA was found in 38 cases (61%). Twenty-five cases (40%) showed at least 5% and up to 80% PSMA(%neg). PSMA(%neg), infiltrative growth pattern, smaller tumour area and diameter and WHO/ISUP grade group 2 significantly correlated with lower SUVmax values. A ROC curve analysis revealed 20% PSMA(%neg) as an optimal cutoff with the highest sensitivity and specificity (89% and 86%, AUC 0.923) for a negative PSMA-PET scan. A multiple logistic regression model revealed tumoural PSMA(%neg) (p < 0.01, OR = 9.629) and growth pattern (p = 0.0497, OR = 306.537) as significant predictors for a negative PSMA-PET scan. Conclusions We describe PSMA(%neg), infiltrative growth pattern, smaller tumour size and WHO/ISUP grade group 2 as parameters associated with a lower Ga-68-PSMA-11 uptake in prostate cancer. These findings can serve as fundament for future biopsy-based biomarker development to enable an individualized, tumour-adapted imaging approach.
conferenceObject Hot needles can confirm accurate lesion sampling intraoperatively using [F-18]PSMA-1007 PET guided biopsy in patients with suspected prostate cancer(2021) LAUDICELLA, R.; FERRARO, D. A.; ZEIMPEKIS, K. G.; MEBERT, I.; MUELLER, J.; DONATI, O.; SAPIENZA, M. T.; RUSCHOFF, J. H.; RUPP, N.; EBERLI, D.; BURGER, I. A.conferenceObject Infiltrative growth-pattern on histopathology is associated with lower diffusion restriction: a potential reason for false-negative mpMRI in prostate cancer(2021) LAUDICELLA, R.; RUSCHOFF, J. H.; FERRARO, D. A.; HAUSMANN, D.; MEBERT, I.; MAURER, A.; HERMANNS, T.; EBERLI, D.; RUPP, N.; BURGER, I. A.